S. Poondru

R. Boinpally, B. Jasti, S. Poondru, 2003, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Identification of 3-amido-4-anilinoquinolines as potent and selective inhibitors of CSF-1R kinase.

David A. Scott, Audrey M Davies, M. Zinda, 2009, Bioorganic & medicinal chemistry letters.

Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.

A. Oza, M. Gore, H. Hirte, 2018, Gynecologic oncology.

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors

C. Rudin, S. Gadgeel, R. Gedrich, 2016, Clinical Cancer Research.

A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies

P. LoRusso, D. Tan, S. Kaye, 2016, British Journal of Cancer.

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies

G. Demetri, S. Gwyther, M. Leach, 2013, Clinical Cancer Research.

Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF- 1R) and insulin receptor (IR) in patients with advanced solid tumors.

Edward S. Kim, Robin L. Jones, S. Lippman, 2010 .

Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI‐906) or Placebo in Chemotherapy‐Naive Patients With Non–Small‐Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations

C. Rudin, M. Ahn, P. Sunpaweravong, 2017, Clinical lung cancer.

Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer

Michael Thomas, Keunchil Park, T. Ciuleanu, 2017, British Journal of Cancer.

Pharmacokinetics of Diethylcarbamazine after Single Oral Dose at Two Different Times of Day in Human Subjects

R. Boinpally, B. Jasti, S. Poondru, 2002, Journal of clinical pharmacology.

Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.

T. Choueiri, E. Baudin, M. Fassnacht, 2015, The Lancet. Oncology.

A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma.

T. Choueiri, C. Kollmannsberger, D. Heng, 2020, The Oncologist.

Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.

Xiaoling Xie, Jingrong Cao, Alex M Aronov, 2009, Journal of medicinal chemistry.

Delivery Strategies to Improve In Vivo Stability of Immunogenic Peptide PADRE

B. Jasti, Poonam Saraf, V. Purohit, 2012 .

High-performance liquid chromatographic method for the estimation of the novel investigational anti-cancer agent SR271425 and its metabolites in mouse plasma.

R. Parchment, T. Corbett, B. Jasti, 2001, Journal of chromatography. B, Biomedical sciences and applications.

Chronopharmacokinetics of Sumatriptan in Healthy Human Subjects

R. Boinpally, S. Poondru, R. Devaraj, 2000, The Journal of pharmacy and pharmacology.

Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors.

I. Puzanov, E. Chan, C. Lindsay, 2010 .

Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors.

I. Puzanov, E. Chan, C. Lindsay, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation of serum and salivary levels of pentoxifylline.

R. Boinpally, S. Poondru, R. Devaraj, 2000, Therapeutic drug monitoring.

A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors

J. Berlin, I. Puzanov, E. Chan, 2014, Clinical Cancer Research.

Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: Interim results from an ongoing phase 1 study.

G. Giaccone, G. Oxnard, A. Krivoshik, 2016 .

Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC.

G. Giaccone, G. Oxnard, A. Krivoshik, 2015 .

Iontophoresis of lecithin vesicles of cyclosporin A.

R. Boinpally, B. Jasti, S. Poondru, 2004, International journal of pharmaceutics.

Clinical pharmacology of the antibody-drug conjugate enfortumab vedotin in advanced urothelial carcinoma and other malignant solid tumors.

P. Bonate, J. Rosenberg, T. Kadokura, 2022, Journal of Clinical Oncology.

A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations

G. Giaccone, G. Oxnard, A. Krivoshik, 2017, Clinical Cancer Research.

Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors.

S. Lippman, S. Kaye, C. Carden, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors.

H. Hirte, C. Sessa, S. Kaye, 2011, Journal of Clinical Oncology.

Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.

C. Rudin, S. Eckhardt, S. Gadgeel, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final results of a phase I study evaluating the combination of linsitinib, a dual inhibitor of insulin-like growth factor-1 receptor (IGF-1R), and insulin receptor (IR) with weekly paclitaxel (PAC) in patients (Pts) with advanced solid tumors.

H. Hirte, C. Sessa, S. Kaye, 2013 .

Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.

G. Bemis, F. Maltais, J. Janetka, 2009, Journal of medicinal chemistry.

Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates.

P. Bonate, M. Jamei, R. Rose, 2023, Journal of Pharmacokinetics and Pharmacodynamics.

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors

C. Rudin, S. Gadgeel, R. Gedrich, 2016, Clinical Cancer Research.

Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors

Edward S. Kim, Robin L. Jones, S. Lippman, 2014, Clinical Cancer Research.

Identification of 3-amido-4-anilinoquinolines as potent and selective inhibitors of CSF-1R kinase.

David A. Scott, Audrey M Davies, M. Zinda, 2009, Bioorganic & medicinal chemistry letters.